Related Experiment Video
Updated: Jun 9, 2025

Heterotopic Auxiliary Whole Liver Rat Transplant Model Utilizing a Hepaticoureterostomy for Allograft Rejection Studies
Published on: March 8, 2024
Risk Stratification for Chronic Kidney Disease After Liver Transplant for Metabolic Dysfunction-associated
Sanjaya K Satapathy1, Saleh Elwir2, Danielle Brandman3
1Northwell Health Center for Liver Diseases and Transplantation, Northshore University Hospital/Northwell Health, Manhasset, NY.
Insights
Liver transplantation in MASH cirrhosis patients impacts kidney function differently based on baseline eGFR. Early post-transplant monitoring is key for managing chronic kidney disease (CKD) risk.
Area of Science:
- Nephrology
- Hepatology
- Transplantation Medicine
Background:
- Chronic kidney disease (CKD) is a significant complication following liver transplantation (LT), especially in patients with metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis.
- MASH is a growing cause of cirrhosis and liver failure, necessitating a better understanding of post-LT renal outcomes.
Purpose of the Study:
- To refine risk stratification for CKD events after LT in MASH cirrhosis patients.
- To investigate the impact of baseline renal function (eGFR) on post-LT kidney function trajectories.
Main Methods:
- Analysis of 717 MASH cirrhosis patients who underwent LT (1997-2017) across 7 US centers.
- Categorization of patients into low (LGFR), medium (MGFR), and high (HGFR) baseline eGFR groups.
- Examination of eGFR changes, identifying a 3-month 'reset point,' and assessing advanced CKD (aCKD) events.
Main Results:
- Patients with low baseline eGFR (LGFR) showed improved eGFR post-LT, while high baseline eGFR (HGFR) patients experienced a decline.
- A 3-month post-LT mark served as a reset point for eGFR trajectories.
- LGFR patients had a significantly higher probability of developing advanced CKD compared to MGFR and HGFR groups.
Conclusions:
- Baseline eGFR significantly influences post-LT renal function trajectories in MASH cirrhosis patients, with a notable reset at 3 months.
- Close monitoring of renal function post-LT is essential, particularly for patients at risk of advanced CKD.
- Further research into interventions for renal dysfunction in MASH patients post-LT is warranted.
Background:
Chronic kidney disease (CKD) is a well-recognized complication in patients undergoing liver transplantation (LT), particularly those with metabolic dysfunction-associated steatohepatitis (MASH), a leading cause of cirrhosis in the modern era. This study sought to refine risk stratification for CKD events post-LT in cirrhosis patients with MASH by leveraging baseline renal function at transplant.
Methods:
A total of 717 MASH cirrhosis patients who had LT (1997-2017) at 7 US centers (NailMASH Consortium) were analyzed. Patients were categorized by estimated glomerular filtration rate (eGFR) at transplant: low (LGFR, eGFR ≤30 mL/min/1.73 m²), medium (MGFR, eGFR >30-≤60 mL/min/1.73 m²), and high (HGFR, eGFR >60 mL/min/1.73 m²). Time-related eGFR intercepts, slopes, and assessments of advanced-stage CKD (aCKD) events, defined as 2 eGFR levels <30 mL/min/1.73 m² separated by ≥90 d, were examined.
Results:
Post-LT, LGFR group showed increased eGFR, whereas the HGFR group experienced a decline. The 3-mo mark was identified as a "reset point," signifying a new reference level, beyond which a different rate of decline was observed. After 3 mo, mean eGFRs of the LGFR group approached MGFRs, whereas the mean eGFR of the HGFR group continued to decrease but remained higher than other groups during a 60-mo follow-up. LGFR patients had significantly higher aCKD probability than MGFR and HGFR groups. Subanalysis at 3 mo post-LT revealed more aCKD events in the LGFR group compared with MGFR and HGFR groups ( P < 0.0001).
Conclusions:
The study underscores renal impact of LT in MASH cirrhosis, indicating unique eGFR trajectories post-LT tied to baseline eGFR, with a reset point at 3 mo. Monitoring post-LT renal function, especially in those at aCKD risk, is crucial. Renal-sparing immunosuppression may help, regardless of baseline eGFR. Further studies are needed for interventions addressing renal dysfunction of patients with MASH post-LT.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management

